Furthermore, the effects of active
vs. placebo treatment on insulin sensitivity was compared.
Not exact matches
The average spine BMD also increased more in the
treatment group than
placebo group at 12 months (3 percent
vs. 1.1 percent) and at 24 months (4.5 percent
vs. 0.7 percent).
This revealed significantly different changes in MCR after
treatment (+27 %
vs. placebo; p <.01).
In a trial of dogs with allergic dermatitis,
treatment success, as defined by owner - assessed decrease in pruritus, occurred in 67 percent of dogs treated with APOQUEL
vs. 29 percent of dogs treated with
placebo after one week of
treatment.
In a clinical trial of dogs with atopic dermatitis,
treatment success for pruritus occurred in a significantly greater percentage of the dogs treated with APOQUEL (66 percent)
vs. (4 percent) of dogs treated with
placebo (p < 0.0001).